Our pre-clinical data show that the CAM1615HER2 TriKE induces activity against HER2-expressing tumors, activates NK cells via CD16 resulting in specific killing of ovarian cancer spheroids, drives specific NK cell expansion, and induces control of the ovarian tumor in vivo. Here, ERBB2 is linked to ovarian neoplasm.